AZELIRAGON

Details

Stereochemistry	ACHIRAL
Molecular Formula	C32H38ClN3O2
Molecular Weight	532.116
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1=NC(=CN1C2=CC=C(OC3=CC=C(Cl)C=C3)C=C2)C4=CC=C(OCCCN(CC)CC)C=C4

InChI

InChIKey=KJNNWYBAOPXVJY-UHFFFAOYSA-N

InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C32H38ClN3O2
Molecular Weight	532.116
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.alzforum.org/therapeutics/azeliragon | http://vtvtherapeutics.com/pipeline/azeliragon

Azeliragon is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproducts (RAGE). RAGE has been proposed to contribute to Alzheimer's disease pathology by promoting vascular leakage, promoting influx of peripheral amyloid beta into brain, mediating amyloid beta induced oxidative stress, mediating AGE induced hyperphosphorylation of tau and amyloid beta mediated neuronal death. Azeliragon is in Phase III clinical trial for the treatment of mild Alzheimer's disease.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Advanced glycosylation end product-specific receptor 1 Target ID: CHEMBL2176846 Sources: http://vtvtherapeutics.com/pipeline/azeliragon	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 272 Sources: http://vtvtherapeutics.com/pipeline/azeliragon	Primary		Phase III 656	AZELIRAGON Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00ECVW	https://www.1pchem.com/search?query=1P00ECVW
AChemBlock	O33796	http://www.achemblock.com/catalogsearch/result/?q=O33796
Alfa Chemistry	603148-36-3	http://www.alfa-chemistry.com/search.aspx?q=603148-36-3
Alfa Chemistry	ACM603148363	http://www.alfa-chemistry.com/search.aspx?q=ACM603148363
Ambeed	A124655	http://www.ambeed.com/search/Search.html?keyword=A124655
AstaTech	N11192	http://astatechinc.com/CPSResult.php?CRNO=N11192
BLD Pharm	BD583929	http://www.bldpharm.com/search/Search.html?keyword=BD583929
Chem Scene	CS-5117	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5117
ChemShuttle	138994	https://www.chemshuttle.com/catalogsearch/result/?q=138994
Combi-Blocks	QW-1950	http://www.combi-blocks.com/cgi-bin/find.cgi?QW-1950
Excenen	EX-A1834	http://www.excenen.com/searchresultlist.php?id=EX-A1834
Hairui	AZXM008	http://www.hairuichem.com/en/product/search.do?q=AZXM008
KeyOrganics	AS-49837	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-49837
MedChem Express	HY-50682	https://www.medchemexpress.com/search.html?q=HY-50682&ft=&fa=&fp=
MolPort	MolPort-042-676-233	https://www.molport.com/shop/molecule-link/MolPort-042-676-233
Molnova	M15253	https://www.molnova.com/en/serch-list.html?keywords=M15253
MuseChem	I004271	https://www.musechem.com/product/I004271.html
MuseChem	I006440	https://www.musechem.com/product/I006440.html
Selleck Chemicals	S6415	http://www.selleckchem.com/search.html?searchDTO.searchParam=S6415
ShangHai Biochempartner	BCP16862	http://www.biochempartner.com/search_BCP16862
TargetMol	T2507	https://www.targetmol.com/search?keyword=T2507
Tetrahedron	TS94700	http://www.thsci.com/search.do?q=TS94700
eMolecules	72973158	https://orderbb.emolecules.com/search/#?query=72973158
eNovation Chemicals	D509236	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D509236&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-2610188504	https://mcule.com/MCULE-2610188504/

PubMed

Title	Date	PubMed
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.	2003 Jul	12808450
New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.	2014	25368578
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.	2014 Jan 15	24423155

Patents

Sample Use Guides

In Vivo Use Guide

Azeliragon 5 mg orally once daily for 2 years.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:52:26 GMT 2023` Edited by `admin` on `Sat Dec 16 17:52:26 GMT 2023`
Record UNII	LPU25F15UQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZELIRAGON

Official Name

English

azeliragon [INN]

Common Name

English

TTP-488

Code

English

1-PROPANAMINE, 3-(4-(2-BUTYL-1-(4-(4-CHLOROPHENOXY)PHENYL)-1H-IMIDAZOL-4-YL)PHENOXY)-N,N-DIETHYL-

Systematic Name

English

TTP488

Code

English

3-(4-{2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethylpropan-1-amine

Systematic Name

English

Azeliragon [WHO-DD]

Common Name

English

AZELIRAGON [USAN]

Common Name

English

PF-04494700

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

915922